Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

42 results

Filters applied: . Clear all
Page 1
The Role of ICS-Containing Rescue Therapy Versus SABA Alone in Asthma Management Today.
Krings JG, Beasley R. Krings JG, et al. Among authors: beasley r. J Allergy Clin Immunol Pract. 2024 Apr;12(4):870-879. doi: 10.1016/j.jaip.2024.01.011. Epub 2024 Jan 17. J Allergy Clin Immunol Pract. 2024. PMID: 38237858 Review.
In this review, we compare, using a pros and cons format, the (1) long-term safety and efficacy of ICS-formoterol reliever therapy versus SABA reliever therapy alone, (2) long-term safety and efficacy of ICS-albuterol reliever therapy versus SABA reliever therapy al …
In this review, we compare, using a pros and cons format, the (1) long-term safety and efficacy of ICS-formoterol reliever therapy ve …
The Anti-Inflammatory Reliever (AIR) Algorithm Study: a protocol for a single-group study of an AIR stepwise approach to the treatment of adult asthma.
Bruce P, Hatter L, Houghton C, Kearns C, Holliday M, Anderson AJ, Eathorne A, Martindale J, Semprini A, Weatherall M, Pavord I, Harrison T, Papi A, Horne R, Beasley R. Bruce P, et al. Among authors: beasley r. ERJ Open Res. 2023 Sep 25;9(5):00239-2023. doi: 10.1183/23120541.00239-2023. eCollection 2023 Sep. ERJ Open Res. 2023. PMID: 37753283 Free PMC article.
BACKGROUND: The stepwise approach to long-term asthma management, which traditionally incorporates short-acting beta(2)-agonist reliever therapy, has been a core feature of asthma guidelines for over 30 years. ...
BACKGROUND: The stepwise approach to long-term asthma management, which traditionally incorporates short-acting beta(2)-agonist relie …
Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial.
Writing Committee for the REMAP-CAP Investigators; Higgins AM, Berry LR, Lorenzi E, Murthy S, McQuilten Z, Mouncey PR, Al-Beidh F, Annane D, Arabi YM, Beane A, van Bentum-Puijk W, Bhimani Z, Bonten MJM, Bradbury CA, Brunkhorst FM, Burrell A, Buzgau A, Buxton M, Charles WN, Cove M, Detry MA, Estcourt LJ, Fagbodun EO, Fitzgerald M, Girard TD, Goligher EC, Goossens H, Haniffa R, Hills T, Horvat CM, Huang DT, Ichihara N, Lamontagne F, Marshall JC, McAuley DF, McGlothlin A, McGuinness SP, McVerry BJ, Neal MD, Nichol AD, Parke RL, Parker JC, Parry-Billings K, Peters SEC, Reyes LF, Rowan KM, Saito H, Santos MS, Saunders CT, Serpa-Neto A, Seymour CW, Shankar-Hari M, Stronach LM, Turgeon AF, Turner AM, van de Veerdonk FL, Zarychanski R, Green C, Lewis RJ, Angus DC, McArthur CJ, Berry S, Derde LPG, Gordon AC, Webb SA, Lawler PR. Writing Committee for the REMAP-CAP Investigators, et al. JAMA. 2023 Jan 3;329(1):39-51. doi: 10.1001/jama.2022.23257. JAMA. 2023. PMID: 36525245 Free PMC article.
IMPORTANCE: The longer-term effects of therapies for the treatment of critically ill patients with COVID-19 are unknown. OBJECTIVE: To determine the effect of multiple interventions for critically ill adults with COVID-19 on longer-term outcomes. DESIGN, SETTING, AN …
IMPORTANCE: The longer-term effects of therapies for the treatment of critically ill patients with COVID-19 are unknown. OBJECTIVE: T …
Percutaneous mechanical thrombectomy in a real-world pulmonary embolism population: Interim results of the FLASH registry.
Toma C, Bunte MC, Cho KH, Jaber WA, Chambers J, Stegman B, Gondi S, Leung DA, Savin M, Khandhar S, Kado H, Koenig G, Weinberg M, Beasley RE, Roberts J, Angel W, Sarosi MG, Qaqi O, Veerina K, Brown MA, Pollak JS. Toma C, et al. Among authors: beasley re. Catheter Cardiovasc Interv. 2022 Mar;99(4):1345-1355. doi: 10.1002/ccd.30091. Epub 2022 Feb 3. Catheter Cardiovasc Interv. 2022. PMID: 35114059 Free PMC article.
BACKGROUND: High- and intermediate-risk PEs are characterized by high mortality rates, frequent readmissions, and long-term sequelae. Mechanical thrombectomy is emerging as a front-line therapy for PE that enables immediate thrombus reduction while avoiding the bleeding ri …
BACKGROUND: High- and intermediate-risk PEs are characterized by high mortality rates, frequent readmissions, and long-term sequelae. …
Towards a personalised treatment approach for asthma attacks.
Martin MJ, Beasley R, Harrison TW. Martin MJ, et al. Among authors: beasley r. Thorax. 2020 Dec;75(12):1119-1129. doi: 10.1136/thoraxjnl-2020-214692. Epub 2020 Aug 24. Thorax. 2020. PMID: 32839286 Review.
The recognition of asthma as a heterogeneous condition with multiple phenotypes has revolutionised the approach to the long-term management of the condition, with greater emphasis on personalised treatment and the introduction of the treatable traits concept. ...
The recognition of asthma as a heterogeneous condition with multiple phenotypes has revolutionised the approach to the long-term mana …
Asthma and Respiratory Foundation NZ Adolescent and Adult Asthma Guidelines 2020: a quick reference guide.
Beasley R, Beckert L, Fingleton J, Hancox RJ, Harwood M, Hurst M, Jones S, Jones S, Kearns C, McNamara D, Poot B, Reid J. Beasley R, et al. N Z Med J. 2020 Jun 26;133(1517):73-99. N Z Med J. 2020. PMID: 32595223 Review.
The main changes in the 2020 update are: 1) combining the recommendations for both adolescents and adults in a single document, 2) the recommendation to avoid SABA-only treatment in the long-term management of asthma, 3) the use of budesonide/formoterol reliever, with or w …
The main changes in the 2020 update are: 1) combining the recommendations for both adolescents and adults in a single document, 2) the recom …
Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial.
Busse WW, Bleecker ER, FitzGerald JM, Ferguson GT, Barker P, Sproule S, Olsson RF, Martin UJ, Goldman M; BORA study investigators. Busse WW, et al. Lancet Respir Med. 2019 Jan;7(1):46-59. doi: 10.1016/S2213-2600(18)30406-5. Epub 2018 Nov 8. Lancet Respir Med. 2019. PMID: 30416083 Clinical Trial.
BACKGROUND: Benralizumab is an interleukin-5 receptor alpha-directed cytolytic monoclonal antibody that has been shown to safely reduce exacerbations and improve lung function for patients with asthma. We assessed the long-term safety and efficacy of benralizumab for patie …
BACKGROUND: Benralizumab is an interleukin-5 receptor alpha-directed cytolytic monoclonal antibody that has been shown to safely reduce exac …
Oxygen versus air-driven nebulisers for exacerbations of chronic obstructive pulmonary disease: a randomised controlled trial.
Bardsley G, Pilcher J, McKinstry S, Shirtcliffe P, Berry J, Fingleton J, Weatherall M, Beasley R. Bardsley G, et al. Among authors: beasley r. BMC Pulm Med. 2018 Oct 3;18(1):157. doi: 10.1186/s12890-018-0720-7. BMC Pulm Med. 2018. PMID: 30285695 Free PMC article. Clinical Trial.
The primary analysis used a mixed linear model with fixed effects of the baseline PtCO(2), time, the randomised intervention, and a time by intervention interaction term; to estimate the difference between randomised treatments at 35 min. ...
The primary analysis used a mixed linear model with fixed effects of the baseline PtCO(2), time, the randomised intervention, and a time by …
Physiological effects of titrated oxygen via nasal high-flow cannulae in COPD exacerbations: A randomized controlled cross-over trial.
Pilcher J, Eastlake L, Richards M, Power S, Cripps T, Bibby S, Braithwaite I, Weatherall M, Beasley R. Pilcher J, et al. Among authors: beasley r. Respirology. 2017 Aug;22(6):1149-1155. doi: 10.1111/resp.13050. Epub 2017 May 4. Respirology. 2017. PMID: 28470831 Clinical Trial.
The reduction in respiratory rate for NHF at 30 min was not statistically significant (-2.0 breaths/min (95% CI: -4.5 to 0.4), P = 0.099). CONCLUSION: Short-term use of NHF results in a small reduction in PtCO(2) compared with SNP in patients with acute exacerbations of CO …
The reduction in respiratory rate for NHF at 30 min was not statistically significant (-2.0 breaths/min (95% CI: -4.5 to 0.4), P = 0.099). C …
42 results